

Supplementary material

Smukowska-Gorynia A, Iwańczyk S, Rzymiski P, et al. Patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension during the COVID-19 pandemic (2020–2022): clinical outcomes, prognostic factors, and response to vaccination. Pol Arch Intern Med. 2024; 134: 16706. doi:10.20452/pamw.16706

Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.

Table S1 Detailed patients characteristic

n=88		
Gender		
Female n (%)	54	(61)
Male n (%)	34	(39)
Age years	58	46-69
Specific treatment		
Sildenafil n (%)	53	(60)
Bosentan n (%)	30	(34)
Macitentan n (%)	24	(27)
Selexypag n (%)	7	(8)
Riociguat n (%)	25	(28)
Treprostinil (iv and sc) n (%)	20	(23)
Epoprostenol iv n (%)	2	(2)
Iloprost inhaled n (%)	8	(9)
Etiology n (%)		
IPAH	33	(38)
PAH-CTD	11	(12)
PAH-CHD	16	(18)
PoP-PAH	2	(2)
CTEPH	26	(30)
WHO FC n (%)		
I	1	(1)
II	39	(44)
III	47	(54)
IV	1	(1)
mPAP mmHg	45	32-51
PVR dynes * s * cm ⁻⁵	496	320-730
CI l/min/m ²	2.9	2.4-3.4
Sat mix O ₂ %	74.3	68.3-77.8
mRAP mmHg	7	3-9
NT-proBNP pg/ml	485	163-2066
RDW %	14.5	13.8-15.5
Troponin I ng/ml	0.014	0.006-0.038
sCOV BAU/ml	322.6	53.1-1170.1
RAA cm ²	20.5	17-29.5
Fluid in pericardium n (%)	13	(15)
6MWT m	425	330-490

CI: cardiac index; CTEPH: chronic thromboembolic pulmonary hypertension; IPAH: idiopathic pulmonary arterial hypertension; mPAP: mean pulmonary arterial pressure; mRAP: mean right atrium pressure; NT-proBNP: N-terminal fragment of brain pro-peptide; PAH-CHD: pulmonary arterial hypertension associated with congenital heart disease; PAH-CTD: pulmonary arterial hypertension associated with connective tissue diseases; PoPAH: porto-pulmonary arterial hypertension; PVR: pulmonary vascular resistance; RDW: red blood cells distribution width; RAA: right atrium area; Sat mixO₂: mixed venous blood oxygen saturation; 6MWT: six minute walking test; sCOV: anti-spike antibodies; WHO FC: World Health Organization Functional Class;

Table S2 Univariable Cox regression analysis of risk factors of mortality due to COVID-19.

	HR	95%CI	P value
No vaccination	1.31		<0.001
Age	1.11	1.02-1.21	0.02
mRAP	1.26	1.06-1.50	0.01
Sat mixO ₂	0.84	0.72-0.99	0.02
RDW	2.25	1.21-4.19	0.01
6MWT	0.97	0.94-1.00	0.01
RAA	1.05	1.01-1.09	0.047

mRAP: mean right atrium pressure; RAA: right atrium area; RDW: red blood cells distribution width; 6MWT: six minute walking test; Sat mixO₂: mixed venous blood oxygen saturation

Table S3 Univariable and multivariable Cox regression analysis of risk factors of all-cause mortality and disease worsening due to right ventricle failure progression.

Univariable analysis				Multivariable analysis		
	HR	95%CI	P value	HR	95%CI	P value
WHO FC	0.014	1.29-9.87	0.01	0.96	0.22-4.14	0.96
mPAP	1.04	1.00-1.07	0.04	1.03	0.97-1.09	0.39
mRAP	1.15	1.03-1.29	0.02	1.01	0.88-1.17	0.86
RAA	1.10	1.04-1.16	0.001	1.18	1.07-1.30	0.001
RDW	1.78	1.34-2.35	<0.001	2.99	1.64-5.47	<0.001

mPAP: mean pulmonary artery pressure; mRAP: mean right atrium pressure; RAA: right atrium area; RDW: red blood cells distribution width; WHO FC: World Health Organization Functional Class;